This update is relevant to pulmonologists, allergy specialists, primary care clinicians, and pharmacists who manage adult patients with persistent asthma requiring controller escalation, and to clinicians treating adolescents aged 12 years and older for BREZTRI where applicable ^[1][2][3]. The labeling supports selection among triple-combination inhalers that differ by dosing frequency (once-daily TRELEGY versus twice-daily TRIMBOW and BREZTRI), component molecules, and age approvals, providing options when stepping up therapy or matching patient factors such as adherence patterns and prior ICS exposure ^[1][2][3]. What remains unanswered is how to prioritize one triple combination over another for individual severe asthma phenotypes in the absence of head-to-head comparative efficacy data in the provided excerpts?

Q1 What is Trimbow approved for?

Trimbow (beclomethasone dipropionate/formoterol fumarate/glycopyrrolate) is approved for the maintenance treatment of asthma in adult patients aged 18 years and older, per the 2026 prescribing highlights. The label states it is not indicated for relief of acute bronchospasm and provides recommended dosing options and limitations of use. Clinicians should consult current prescribing information for full dosing guidance.

Q2 How does Trimbow work?

Trimbow is a fixed-dose triple inhaler combining an inhaled corticosteroid (beclomethasone dipropionate), a long-acting beta2-adrenergic agonist (formoterol fumarate), and an anticholinergic long-acting muscarinic antagonist (glycopyrrolate); the label describes these components and their combined role as maintenance therapy for asthma control in adults. The prescribing highlights list mechanism classes for each component but do not provide comparative mechanistic data versus other triple products.

Q3 What is the dose?

Trimbow recommended dosing in the highlights includes TRIMBOW 172 mcg/9.8 mcg/21.2 mcg (administered as 2 actuations of 86 mcg/4.9 mcg/10.6 mcg) twice daily and TRIMBOW 344 mcg/9.8 mcg/21.2 mcg twice daily, with starting dose selection based on asthma severity or level of control on current inhaled corticosteroids; for BREZTRI the asthma maintenance dose is budesonide 320 mcg/glycopyrrolate 36 mcg/formoterol 9.6 mcg administered as 2 inhalations of BREZTRI 160 mcg/18 mcg/4.8 mcg twice daily, and TRELEGY starting options for asthma are 100/62.5/25 mcg or 200/62.5/25 mcg once daily. Clinicians should consult current prescribing information for complete dosing guidance.

Q4 What are the side effects?

Label-reported adverse reactions for Trimbow (incidence ≥ 1%) include bronchitis, hypertension, back pain, blood pressure increased, dysphonia, upper respiratory tract infection, influenza, anemia, muscle spasms, laryngitis, oropharyngeal pain, and sinusitis. BREZTRI asthma labeling lists nasopharyngitis, pneumonia, and headache as most common adverse reactions (incidence ≥ 2%). TRELEGY highlights and warnings name risks including oropharyngeal candidiasis, increased risk of pneumonia (in COPD populations), potential worsening of infections, impaired adrenal function on corticosteroid withdrawal, hypercorticism and adrenal suppression, paradoxical bronchospasm, cardiovascular effects, reductions in bone mineral density, glaucoma and cataracts, urinary retention, and alerts for hypokalemia and hyperglycemia.

Clinicians should consult current prescribing information for complete dosing guidance.